S'abonner

Research progress on plant-derived exosome-like nanovesicles in regulating and promoting tissue repair - 07/11/26

Doi : 10.1016/j.biopha.2026.119936 
Junrui Li a, c, d, Xuhao Ji a, c, d, Yan Xue a, c, d, Jiabing Shen c, e, ⁎ , Jun Tan a, b, ⁎
a Department of Hand Surgery, Affiliated Hospital of Nantong University, Nantong 226001, China 
b Hand Surgery Research Center, Affiliated Hospital of Nantong University, Nantong 226001, China 
c Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China 
d Medical School of Nantong University, Nantong 226001, China 
e Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, China 

⁎ Corresponding author at: Department of Neurology, Affiliated Hospital of Nantong University, Nantong 226001, China. Department of Neurology, Affiliated Hospital of Nantong University Nantong 226001 China ⁎⁎ Correspondence to: Department of Hand Surgery, Affiliated Hospital and Medical School of Nantong University, Nantong 226001, China. Department of Hand Surgery, Affiliated Hospital and Medical School of Nantong University Nantong 226001 China

Abstract

Background

Plant-derived exosomes or exosome-like nanovesicles (PELNVs) constitute a distinct branch within the broader exosome concept. As natural nanocarriers, PELNVs hold considerable therapeutic potential in tissue repair and regenerative medicine, offering multiple advantages such as moderate biocompatibility, potentially lower immunogenicity, and the intrinsic bioactivity of medicinal plants. Furthermore, PELNVs overcome several limitations associated with mammalian-derived exosomes, including low yield, high production costs, potential safety concerns, and the risk of autologous rejection.

Objective

This study aims to review current progress in the field by systematically examining literature encompassing nearly 30 plant species analyzed in depth. The review summarizes recent findings regarding the role of PELNVs in promoting tissue repair, including wound healing, bone regeneration, neuroprotection, and related applications. These findings are categorized according to plant species and mechanisms of repair, enabling a critical evaluation of the therapeutic effects of PELNVs across different organ systems.

Methods

A comprehensive literature search and analysis were conducted based on approximately 73 publications retrieved from PubMed and Medline, spanning the period from 2020 to June 2026. Keywords related to plant- and herb-derived exosomes, nanoparticles, and vesicles were combined with terms pertaining to tissue repair. The analysis focused primarily on in vitro and in vivo studies investigating PELNVs in tissue repair. Key aspects examined included plant species, vesicle isolation methods, target cells, and therapeutic outcomes. In addition, high-impact references published between 2020 and 2026 were incorporated to contextualize these findings within the broader biomedical literature. Subsequently, mechanistic pathways and application domains were systematically organized and analyzed.

Conclusion

PELNVs may represent a promising frontier in regenerative medicine and tissue repair, demonstrating significant potential as wound-healing accelerators, anti-inflammatory agents, and microRNA delivery vehicles. However, limited long-term toxicological and immunogenicity data currently preclude firm conclusions regarding safety and clinical readiness. Further research is required to standardize large-scale production methods and elucidate the precise mechanisms of action, ultimately facilitating the clinical translation of plant-based nanotherapeutics.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

Fig.entary Figure.1. Abstract of current types of PLENVs and different mechanisms in tissue repair and regeneration


Fig.entary Figure.1. Abstract of current types of PLENVs and different mechanisms in tissue repair and regeneration

Le texte complet de cet article est disponible en PDF.

Highlights

•
Plant-derived exosome-like nanovesicles (PELNVs) show potentially higher short-term biocompatibility and lower immunogenicity.
•
PELNVs from over 25 medicinal and edible plants promote regeneration across skin, bone, intestine, liver, and nervous system.
•
PELNVs support M2 macrophage polarization, angiogenesis, and stem cell differentiation to create a pro-repair milieu.
•
Standardized isolation, functionalization, and hydrogel delivery are essential for the clinical translation of PELNVs.

Le texte complet de cet article est disponible en PDF.

Abbreviations : AB/PAS, ACLT, ACSL4, ADSCs, AFM, ALT, APBA, Arg-1, AST, ATG7, AV-EVLPs, BCA, BLEN, BLENs, BSDExo, CAE, CCL2, C-CP, CLDENs, CPA, CRGD, Cryo-TEM, DLS, DMM, DSI, DSS, Ems, EP-EVLP, EVs, GAP43, GDE, GDE-Cur, GDEs, GDNPs, GelMA, GF-Exos, GLEN, HaCaT, HBMSCs, HC-EVs@B-CH, HDFa, HDNF, HIEC-6, HoNVS, HT-EVLPs, HUVECs, IDENVs, IL-10, IL-1β, IL-6, INOS, L929, LC3B, LDNs, LNVs, LPS, MAPK, MC3T3-E1, MCAO, MMP-3, MMP-9, MOEVLP, NF-κB, NF200, NTA, OEVs, OVX, PDEVs, PDI, PEG, PELNVs, PL-Exos, PLEVPs, PMOP, PNVs, RhCOL3, ROS, RT-PCR, SEC, SgUC, SiRNA, SmELNs, SNDENs, SQSTM1/p62, TAB1, TEM, TMAO, TNF-α, TPELNVs, VEGF, UC

Keywords : Plant-derived exosome-like nanovesicles, Tissue repair, Wound healing, Regenerative medicine, PELNVs application in targeted organs, Macrophage polarization


Plan


© 2026  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 204

Article 119936- novembre 2026 Retour au numéro
Article précédent Article précédent
  • Natural product-derived compounds modulating STAT3 signaling in prostate cancer: Mechanistic insights and therapeutic potential
  • Yikun Feng, Danming Liu, Chen Gu, Tian Zhou, Ziqi Zhang, Pierre-Antoine Bonnet, Xiangguo Meng
| Article suivant Article suivant
  • A hypothesis-driven perspective on GLP-1R-β-catenin pathway crosstalk in astrocyte plasticity and endogenous neural repair
  • Sudichhya Tamrakar, Laurence S. Pe, Jiraporn Panmanee, Jenq-Lin Yang, Sujira Mukda

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.